Form 8-K - Current report:
SEC Accession No. 0001493152-24-009678
Filing Date
2024-03-12
Accepted
2024-03-12 16:51:30
Documents
20
Period of Report
2024-03-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56867
2 ex10-1.htm EX-10.1 69783
3 ex10-2.htm EX-10.2 99137
4 ex10-3.htm EX-10.3 102516
5 ex10-4.htm EX-10.4 12293
6 ex10-4_001.jpg GRAPHIC 24268
  Complete submission text file 0001493152-24-009678.txt   656777

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE cldi-20240308.xsd EX-101.SCH 3893
8 XBRL DEFINITION FILE cldi-20240308_def.xml EX-101.DEF 26803
9 XBRL LABEL FILE cldi-20240308_lab.xml EX-101.LAB 37082
10 XBRL PRESENTATION FILE cldi-20240308_pre.xml EX-101.PRE 25427
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6130
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 24742965
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)